 |
|
Protein may be strongest indicator of rare lung disease, study shows
June 04, 2009CINCINNATI-Researchers at the University of Cincinnati (UC) have discovered a protein in the lungs that can help in determining progression of the rare lung disease Idiopathic Pulmonary Fibrosis (IPF).
Researchers say the protein-Serum surfactant protein A-is superior to other IPF predictors and could lead to better decisions about treatment and timing of lung transplantation.
The study, led by Brent Kinder, MD, is published in the June 4 edition of the journal Chest.
Surfactant proteins are lipoproteins that allow the lungs to stretch and function. These have previously been investigated by UC pulmonary researchers Frank McCormack, MD, and Jeffrey Whitsett, MD.
Kinder and colleagues report that Serum surfactant protein A is the strongest predictor of a patient's survival in the first year after diagnosis with IPF.
"A simple blood test may give us the information we need to help determine the short term risk of death in a patient with IPF," says Kinder, an assistant professor of medicine at the UC College of Medicine and pulmonologist with UC Physicians. "This protein is a stronger predictor of the severity of illness than age, symptoms or prognostic data, like breathing tests."
IPF is scarring of the lung. As the disease progresses, air sacs in the lungs become replaced by fibrotic scar tissue. Lung tissue becomes thicker where the scarring forms, causing an irreversible loss of the tissue's ability to carry oxygen into the bloodstream.
IPF is one of about 200 disorders called interstitial lung diseases, which affect the thick tissue of the lung as opposed to more common lung ailments-such as asthma or emphysema-that affect the airways.
IPF is the most common form of interstitial lung diseases and affects about 128,000 people in the United States, with an estimated 48,000 new cases diagnosed each year. There currently are no proven therapies or cures for IPF.
Kinder, director of UC's Interstitial Lung Disease Center, says this new indicator will allow doctors to determine the severity of the disease in a fast, effective manner and will help them decide the best way to go about treating it.
"It will allow us to come to a decision about how or if to treat the IPF patient and get them enrolled in clinical trials immediately," he says. "In severe cases, it can help in scheduling a lung transplant at the most optimal time for the patient.
"Overall, this discovery could help us define the window of opportunity to appropriately try more aggressive therapies and could greatly help improve the lives of those living with IPF."
University of Cincinnati Academic Health Center
Surfactant proteins are lipoproteins that allow the lungs to stretch and function. These have previously been investigated by UC pulmonary researchers Frank McCormack, MD, and Jeffrey Whitsett, MD.
Kinder and colleagues report that Serum surfactant protein A is the strongest predictor of a patient's survival in the first year after diagnosis with IPF.
"A simple blood test may give us the information we need to help determine the short term risk of death in a patient with IPF," says Kinder, an assistant professor of medicine at the UC College of Medicine and pulmonologist with UC Physicians. "This protein is a stronger predictor of the severity of illness than age, symptoms or prognostic data, like breathing tests."
IPF is scarring of the lung. As the disease progresses, air sacs in the lungs become replaced by fibrotic scar tissue. Lung tissue becomes thicker where the scarring forms, causing an irreversible loss of the tissue's ability to carry oxygen into the bloodstream.
IPF is one of about 200 disorders called interstitial lung diseases, which affect the thick tissue of the lung as opposed to more common lung ailments-such as asthma or emphysema-that affect the airways.
IPF is the most common form of interstitial lung diseases and affects about 128,000 people in the United States, with an estimated 48,000 new cases diagnosed each year. There currently are no proven therapies or cures for IPF.
Kinder, director of UC's Interstitial Lung Disease Center, says this new indicator will allow doctors to determine the severity of the disease in a fast, effective manner and will help them decide the best way to go about treating it.
"It will allow us to come to a decision about how or if to treat the IPF patient and get them enrolled in clinical trials immediately," he says. "In severe cases, it can help in scheduling a lung transplant at the most optimal time for the patient.
"Overall, this discovery could help us define the window of opportunity to appropriately try more aggressive therapies and could greatly help improve the lives of those living with IPF."
University of Cincinnati Academic Health Center
Lung Disease Current Events and Lung Disease News RSSSurvey: Awareness of COPD is rising, but understanding is still low
Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
Multicenter study led by pitt finds early results of therapy for preemies not sustained
Inhaled nitric oxide (iNO), a therapy used in the treatment of premature newborns with respiratory failure that had shown promising results in short-term studies, does not significantly improve long-term outcomes, according to a national study led by critical care researchers at the University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC.
Geneticists Hunt for Scleroderma Triggers
At its most benign, the autoimmune disease scleroderma can discolor parts of the skin of its sufferers. At its most pernicious, it can thicken and harden their skin, their blood vessels, and their internal organs before, in many cases, killing them.
Thyroid surgery safe for older patients, study finds
Thyroid surgery is safe for older patients, say physicians who found only slight differences in rates of complications and hospital readmissions in a multi-year study.
Drug could provide first treatment for scleroderma
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive.
People who work after retiring enjoy better health, according to national study
Retirees who transition from full-time work into a temporary or part-time job experience fewer major diseases and are able to function better day-to-day than people who stop working altogether, according to a national study.
UT scientists discover link between protein and lung disease
In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).
UAB Researchers Find TB-Prevention Therapy Is Cost-Effective Option
University of Alabama at Birmingham (UAB) researchers have found that the cost of preventive antibiotic tuberculosis (TB) therapy for patients infected by human immunodeficiency virus (HIV) is generally less expensive than the reported cost of treating newly confirmed TB cases.
New vaccine shows promise for COPD patients at risk for pneumonia
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.
New genes at work in patients with hereditary lung disease
University of Florida researchers have safely given new, functional genes to patients with a hereditary defect that can lead to fatal lung and liver diseases, according to clinical trial findings slated to appear this week in the online early edition of the Proceedings of the National Academy of Sciences.
More Lung Disease Current Events and Lung Disease News Articles
 |
Pulmonary Arterial Hypertension and Interstitial Lung Diseases: A Clinical Guide by Robert P. Baughman (Editor), Roberto G. Carbone (Editor), Giovanni Bottino (Editor) Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 150 disorders characterized by scarring or fibrosis of the lungs. In Pulmonary Arterial Hypertension and Interstitial Lung Disease: A Clinical Guide, renowned experts provide a state-of-the-art overview of the problems seen by physicians in the clinical management of ILDs. Divided into two sections, the first part provides and update on general issues and introduces both interstitial lung disease and associated pulmonary hypertension. A detailed analysis of the pathology of the various interstitial lung diseases is also provided. The second part addresses specific categories of disease. Bronchiolitis, hypersensitivity pneumonitis, and other conditions are covered, and the use of inspiratory and... |
 |
Acute Exacerbations of Chronic Obstructive Pulmonary Disease (Lung Biology in Health and Disease) by Nikos Siafakas (Editor), Nicholas R. Anthonisen (Editor), Dimitris Georgopoulos (Editor) Aids practitioners who are looking to more effectively diagnose, treat, and manage patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Discusses pulmonary gas exchange, muscle function and breathing, water/electrolyte imbalances, and end stage disease in AECOPD. |
 |
Fishman's Pulmonary Diseases and Disorders (2-Volume Set) by Alfred Fishman (Author), Jack Elias (Author), Jay Fishman (Author), Michael Grippi (Author), Robert Senior (Author), Allan Pack (Author) A complete guide to the entire field of respiratory medicine--with all-new content and a streamlined new design First published in 1980, Fishman's Pulmonary Diseases and Disorders is the classic reference through which pulmonary physicians have gained a commanding look at the diagnosis and treatment of pulmonary diseases and disorders. Edited by the world's foremost authorities, Fishman's Pulmonary Diseases and Disorders covers exactly what you need to know about lung diseases and their management, including sleep-disordered breathing, COPD, emphysema, and lung cancer, as well as new technological advances and imaging techniques. This unparalleled two-volume resource begins with a compelling overview of up-to-date clinical perspectives, along with the... |
 |
Pulmonary Hypertension (Lung Biology in Health and Disease) by Marc Humbert (Editor), Joseph P. Lynch III (Editor) Written by internationally recognized experts, Pulmonary Hypertension bridges the gap between pulmonology and cardiology to provide clinicians in both disciplines with knowledge of the signs, symptoms, diagnosis, and pharmacologic and surgical treatments for pulmonary hypertension (PH). Through the use of clinical trials, this ground-breaking text supplies a comprehensive review of both the primary and secondary clinical and investigative aspects of this condition. Discussing controversies and concepts in PH diagnosis and management, this guide explores:
|
 |
Sleep Apnea: Implications in Cardiovascular and Cerebrovascular Disease, Second Edition (Lung Biology in Health and Disease) by T. Douglas Bradley (Editor), John Floras (Editor) Sleep Apnea: Implications in Cardiovascular and Cerebrovascular Disease specifically addresses the cardiovascular and cerebrovascular consequences of sleep apnea and is geared toward a broad readership of physicians that will ultimately aid patients suffering from sleep apnea. Key features: STAY UP-TO-DATE-new information on medical research and clinical developments makes this resource a must-read for both clinicians and researchers working in the field OPTIMIZE YOUR DIAGNOSTIC SKILLS-with the latest data on the link between cardiovascular and cerebrovascular consequences of sleep apnea, including clinical trials data IMPROVE TREATMENT AND PATIENT OUTCOMES-with broad coverage of sleep apnea and associated conditions, such as hypertension,... |
|
Interstitial Lung Disease by Marvin I. Schwartz (Author), Talmadge E. King (Author) Aims to provide thorough coverage of the clinical and pathogenic aspects of interstitial lung disease. This edition includes new chapters on imaging techniques, bronchoalveolar lavage, immunology of sarcoidosis and inflammation in interstitial lung disease. | |
 |
High-Resolution CT of the Lung by W. Richard Webb (Author), Nestor L Müller (Author), David P Naidich (Author) The thoroughly revised Fourth Edition of this widely acclaimed volume explains how to use the newest high-resolution CT technology to detect and diagnose lung abnormalities. Still the only complete text on the topic, this compact, affordable reference is written by the foremost experts and provides cutting-edge technical and clinical information. It includes state-of-the-art HRCT scans of interstitial lung diseases and differential diagnosis tables summarizing the most helpful diagnostic features of interstitial and airspace diseases. This edition includes full-color illustrations of histologic findings in lung disease, correlated with HRCT manifestations. Also included are updated HRCT images obtained on multidetector CT scanners with many coronal and sagittal reformations. Two new... |
 |
Respiratory-Circulatory Interactions in Health & Disease (Lung Biology in Health and Disease) by Steven M. Scharf (Editor), Michael R. Pinsky (Editor), Shelly Magder (Editor) Albert Einstein College of Medicine, Bronx, NY. Describes the issues surrounding the reciprocal relationships and interactions between the respiratory and cardiovascular systems, emphasizing humoral and neurophysical interactions seen in diseases leading to cardiorespiratory failure. |
 |
Pharmacotherapy of Asthma (Lung Biology in Health and Disease) by James Li (Editor) Standing as the only text focused on the pharmaceutical treatment of asthma, this reference details the pharmacology, mechanisms of action, efficacy, and safety of every drug currently utilized in the management and care of asthma patients. Internationally renowned authorities distill published practice guidelines, treatment plans, pharmacologic agents, and clinical studies to provide the most authoritative and up-to-date information on the use of medications to control and prevent this common condition. |
 |
Understanding Lung Disease: Pulmonary Fibrosis Part of the award winning public television series Healthy Body/Healthy Mind. Pulmonary Fibrosis is a set of diseases that cause progressive scarring inside the lungs. Over time the lungs are slowly replaced with scar tissue, which causes airways to restrict airflow, making it difficult to breath and to get enough oxygen. Doctors, patients and researchers are hoping clinical trials will lead to a drug that prevents lung function from worsening ultimately allowing patients to live longer. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
| © 2009 BrightSurf.com |